XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
  Hemophilia
  Anaemia
   Darbepoetin Alfa
   Deferasirox
  Polycythemia
  Thalassemias
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Darbepoetin Alfa Channel
subscribe to Darbepoetin Alfa newsletter

Latest Research : Haematology : Anaemia : Darbepoetin Alfa

   DISCUSS   |   EMAIL   |   PRINT
Study Suggests Drug For Chemotherapy-Induced Anemia Can Be Effectively Administered Tri-Weekly
Feb 15, 2006, 20:01, Reviewed by: Dr. Sanjukta Acharya

Compared with patients who received weekly treatment, a fewer number of patients who received treatment every 3 weeks required blood transfusions from week 5 of treatment onwards.

 
Parallel administration of chemotherapy and an anti-anemia drug called darbepoetin alfa every 3 weeks is safe and effective, according to a new study.

Chemotherapy can reduce the bone marrow's ability to produce red blood cells leading to anemia. Anemia is a common side effect among cancer patients receiving chemotherapy. There are drugs available that are often given in conjunction with chemotherapy to counteract anemia. In the United States, one such drug, called darbepoetin, is often given to cancer patients once every week or every other week. In Europe, some anemic cancer patients receive darbepoetin every third week, synchronizing the treatment with chemotherapy administration. However, past studies have not investigated whether dual administration of chemotherapy and darbepoetin every 3 weeks is as safe and effective as the established weekly regimen.

Jean-Luc Canon, M.D., at the Centre Hospitalier Notre Dame et Reine Fabiola in Charleroi, Belgium, and colleagues performed a phase III clinical trial in which 705 anemic cancer patients were randomly assigned to receive darbepoetin treatment every week or every third week at 110 European medical centers.

Compared with patients who received weekly treatment, a fewer number of patients who received treatment every 3 weeks required blood transfusions from week 5 of treatment onwards. Patients taking darbepoetin every third week, synchronized with chemotherapy, had similar hemoglobin levels, and experienced equivalent side effects as patients taking darbepoetin weekly.

The authors conclude that patients with anemia can effectively be treated with darbepoetin every third week with no additional health risks.
 

- February 15 Issue of Journal of the National Cancer Institute
 

jncicancerspectrum.oupjournals.org

 
Subscribe to Darbepoetin Alfa Newsletter
E-mail Address:

 



Related Darbepoetin Alfa News

FDA approves extended dosing of Aranesp
Study Suggests Drug For Chemotherapy-Induced Anemia Can Be Effectively Administered Tri-Weekly
Interim Aranesp data suggest major response in anemic patients with MDS
Interim data suggest major response with Aranesp(R) in anemic patients with MDS
Aranesp dosed every three weeks achieved and maintained target hemoglobin levels
Final results demonstrate Aranesp dosed every two weeks is comparable to Epoetin alfa dosed weekly
Anemia drug reduces transfusions and chemotherapy-related fatigue


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us